Related Experiment Video
Updated: Jul 14, 2026
Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays
Published on: June 13, 2019
A robust, target-driven, cell-based assay for checkpoint kinase 1 inhibitors
Tsuyoshi Ish1, Hiroshi Sootome, Alastair J King
1GlaxoSmithKline K.K., Tsukuba-shi Ibaraki, Japan. hiroshi_sootome@merck.com
Abstract:
Checkpoint kinase 1 (Chk1), a serine/threonine kinase, plays an important role in DNA damage checkpoint control and is an attractive target for cancer treatment. To develop a Chk1-specific cell-based assay, stable clones were established in which Chk1 kinase domain fused at its N-terminus with p53 through 4 tandem repeats of Gly-Gly-Gly-Gly-Ser was expressed in an inducible manner. Chk1 kinase specificity of the phosphorylation of fused p53 was confirmed by the experiments with a kinase-inactive Chk1. Only in the presence of an inducer molecule was phosphorylation of p53 at Ser-15 in the stable clones induced. Furthermore, its assay performance proved acceptable for high-throughput screening applications, judging from the Z' factor values (> 0.77). Finally, the cell-based assay thus established yielded structure-activity relationship data for a small set of test inhibitors of Chk1 within cells. Collectively, these results demonstrate that the established cell-based assay provides a novel and highly sensitive cellular platform for Chk1 inhibitor discovery.
Insights
A novel cell-based assay was developed to specifically detect Checkpoint kinase 1 (Chk1) activity. This highly sensitive platform enables efficient discovery of Chk1 inhibitors for cancer therapy.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- Checkpoint kinase 1 (Chk1) is crucial for DNA damage response and a key target in cancer therapy.
- Developing specific assays for Chk1 is essential for identifying novel cancer treatments.
Purpose of the Study:
- To establish a Chk1-specific cell-based assay for high-throughput screening.
- To validate the assay's performance and utility in structure-activity relationship studies.
Main Methods:
- Engineered stable cell clones expressing an inducible Chk1 kinase domain fused to p53.
- Confirmed Chk1 specificity through phosphorylation of p53 at Ser-15.
- Evaluated assay performance using Z' factor values for high-throughput screening suitability.
Main Results:
- The inducible system successfully demonstrated Chk1-specific phosphorylation of the p53 fusion protein.
- The assay achieved high performance with Z' factor values exceeding 0.77.
- Structure-activity relationship data for Chk1 inhibitors were generated within the cellular context.
Conclusions:
- A novel, sensitive cell-based assay for Chk1 activity has been successfully established.
- This platform is suitable for high-throughput screening and facilitates Chk1 inhibitor discovery.
- The assay provides a valuable tool for advancing cancer therapeutic strategies targeting Chk1.
